摘要:
It is an object of the present invention to provide a conjugate of a duocarmycin derivative and a biotin-modified dimer, which is useful for pretargeting methods. According to the present invention, a compound represented by the following formula (1) or formula (2) is provided:
wherein R 1 and R 2 each independently represent a hydrogen atom, a lower alkyl group, or a lower alkoxycarbonyl group; one of R 3 , R 4 , and R 5 represents -O-L 7 -(Xaa) m -L 6 -N 3 , and the remaining two each independently represent a hydrogen atom, a lower alkyl group, or a lower alkoxycarbonyl group; X represents a reactive group; L 6 and L 7 each independently represent a divalent linking group; Xaa represents an amino acid residue; m represents an integer of 2 to 10; and Me represents a methyl group.
摘要:
It is an object of the present invention to provide a fusion protein of a molecule that recognizes cancer cells or the like and a mutant streptavidin, wherein the fusion protein is for use in the treatment or diagnosis of a cancer. According to the present invention, provided is A fusion protein, wherein an antigen-binding molecule having a molecular weight of 20,000 or less is bound, via a linker sequence, to the N-terminal side and/or C-terminal side of mutant streptavidin which comprises an amino acid sequence having the following mutations (1) to (6) with respect to the amino acid sequence of a core streptavidin as shown in SEQ ID NO: 17 provided that the C-terminal amino acid sequence consisting of Pro-Ser-Ala-Ala-Ser may be partially or entirely deleted, and has a decreased immunogenicity as compared with that of a wild-type streptavidin: (1) a mutation in which the tyrosine residue at position 10 is substituted with serine or threonine; (2) a mutation in which the tyrosine residue at position 71 is substituted with alanine or serine; (3) a mutation in which the arginine residue at position 72 is substituted with lysine; (4) a mutation in which the glutamic acid residue at position 89 is substituted with aspartic acid; (5) a mutation in which the arginine residue at position 91 is substituted with lysine; and (6) a mutation in which the glutamic acid residue at position 104 is substituted with glutamine or asparagine.
摘要:
An object of this invention is to provide a streptavidin mutant reduced in affinity to the naturally-occurring biotin, and to provide a modified biotin which shows a high affinity to such streptavidin mutant reduced in affinity to the naturally-occurring biotin. This invention can provide a compound composed of a dimer of modified biotin, a streptavidin mutant, angsd usage of them.
摘要:
An object of this invention is to provide a streptavidin mutant reduced in affinity to the naturally-occurring biotin, and to provide a modified biotin which shows a high affinity to such streptavidin mutant reduced in affinity to the naturally-occurring biotin. This invention can provide a compound composed of a dimer of modified biotin, a streptavidin mutant, angsd usage of them.
摘要:
It is an object of the present invention to provide a mutant streptavidin with a reduced affinity for natural biotin, and also to provide a modified biotin having a high affinity for the mutant streptavidin with a reduced affinity for natural biotin. According to the present invention, there is provided a reagent kit for use in treatments or diagnoses, which comprises: (a) a mutant streptavidin with a reduced affinity for natural biotin or biocytin; and a modified biotin having a high affinity for the above-described mutant streptavidin.
摘要:
A method of judging vascular disorders as a risk factor of myocardial infarction, angiopathic dementia, etc. at an early date, namely, mild vascular disorders. There is provided a method of judging the degree of mild vascular disorders, characterized in that the level of PTX3 in a test sample is measured with the use of anti-PTX3 monoclonal antibody.
摘要:
To provide a method of determining vasculopathy, which is a risk factor of myocardial infarction, angiopathic dementia, etc., at an early stage thereof (i.e., mild vasculopathy). The present invention provides a method of determining the severity of mild vasculopathy, including determining PTX3 level in an assay sample by use of an anti-PTX3 monoclonal antibody.
摘要:
It is an object of the present invention to provide a mutant streptavidin wherein the immunogenicity (antigenicity) in mammals of a streptavidin is reduced. The present invention provides a mutant streptavidin, which comprises an amino acid sequence in which (a) the arginine residue at position 72 is substituted with another amino acid residue, and (b) any one or more of the tyrosine residue at position 10, the tyrosine residue at position 71, the glutamic acid residue at position 89, the arginine residue at position 91, and the glutamic acid residue at position 104 are substituted with other amino acid residues, with respect to the amino acid sequence of a core streptavidin as shown in SEQ ID NO: 2, and which has decreased immunogenicity as compared with that of a wild-type streptavidin.